Scientists have known for a while that Angelman syndrome is caused by the loss of a specific gene, but they didn't understand ...

At Week 12 of its own phase 1b diabetes study, Lilly reported weight loss of up to 5.8 kg on Foundayo, compared to a 0.5 kg ...

Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as ...

Biogen's CEO has pointed to the company's ability to take five drugs into clinical trials so far this year as evidence of its new focus on early-stage R&D. | Biogen's CEO has pointed to the company's ...

Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...

“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...

Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as proof that the company has a worthy rival to Revolution Medicines in this newly hot cancer space. | Incyte has pointed to ...

Corxel Pharmaceuticals may not have always planned to dust off the special purpose acquisition company (SPAC) route to the ...

BioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to ...

Genmab may have arrived in Spain with updated data from a pair of phase 2 studies from the main prize of its Merus buyout, ...

Despite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can ...

Tango Therapeutics disclosed a 14% reduction in headcount even as the company shared more evidence that its PRMT5 inhibitor ...